background
ebolavirus
induc
lethal
viral
hemorrhag
fever
vhf
human
nonhuman
primat
except
reston
viru
restv
pathogen
human
human
vhf
case
extens
analys
humor
immun
respons
survivor
nonsurvivor
shown
igg
respons
nucleoprotein
np
viral
protein
associ
asymptomat
surviv
outcom
neutral
antibodi
respons
target
ebolavirus
glycoprotein
gp
major
indic
protect
immun
hand
immun
respons
nonhuman
primat
especi
natur
infect
one
yet
elucid
detail
signific
antibodi
respons
np
gp
restvinfect
cynomolgu
macaqu
still
unclear
studi
analyz
humor
immun
respons
cynomolgu
macaqu
use
serum
specimen
obtain
restv
epizoot
philippin
expand
knowledg
immun
respons
natur
restvinfect
nonhuman
primat
result
antibodi
respons
analyz
use
iggelisa
indirect
immunofluoresc
antibodi
assay
ifa
pseudotyp
vsvbase
neutral
nt
assay
antigencaptur
ag
elisa
also
perform
detect
viral
antigen
serum
specimen
found
antigp
respons
antinp
respons
close
correl
neutral
respons
well
clearanc
viremia
sera
restvinfect
cynomolgu
macaqu
addit
analyz
cytokinechemokin
concentr
serum
specimen
found
high
concentr
proinflammatori
cytokineschemokin
convalesc
phase
sera
conclus
result
impli
antibodi
respons
gp
proinflammatori
innat
respons
play
signific
role
recoveri
restv
infect
cynomolgu
macaqu
famili
filovirida
includ
three
genera
ebolaviru
marburgviru
cuevaviru
genu
ebolaviru
current
five
member
bundibugyo
viru
bdbv
ebola
viru
ebov
reston
viru
restv
sudan
viru
sudv
forest
viru
filovirus
induc
lethal
viral
hemorrhag
fever
vhf
human
nonhuman
primat
restv
infect
human
probabl
subclin
yet
also
caus
highli
lethal
vhf
macaqu
restv
epizoot
among
cynomolgu
macaqu
emerg
epizoot
cynomolgu
macaqu
origin
singl
primat
breed
facil
philippin
although
natur
reservoir
restv
remain
unknown
restv
isol
pig
philippin
addit
porcin
reproduct
respiratori
syndrom
viru
prrsv
porcin
circoviru
consid
social
impact
ebolavirus
import
understand
endem
epizoot
statu
restv
philippin
studi
investig
antibodi
respons
cynomolgu
macaqu
could
deadend
host
restv
use
serum
specimen
collect
cynomolgu
macaqu
restv
outbreak
philippin
attempt
elucid
signific
neutral
antibodi
restv
viral
clearanc
previous
establish
enzymelink
immunosorb
assay
elisa
indirect
immunofluoresc
antibodi
assay
ifa
specif
restv
nucleoprotein
np
assay
use
tool
investig
sign
restv
infect
cynomolgu
macaqu
human
case
antibodi
respons
ebolavirus
analyz
extens
igg
respons
np
structur
protein
eg
shown
correl
asymptomat
surviv
case
neutral
antibodi
respons
target
ebolavirus
glycoprotein
gp
appear
major
indic
protect
immun
hand
proinflammatori
cytokineschemokin
known
play
major
role
pathogenesi
ebolavirus
infect
variou
speci
previou
studi
shown
uncontrol
secret
proinflammatori
cytokineschemokin
contribut
fatal
outcom
ebovinfect
human
cynomolgu
macaqu
strong
proinflammatori
cytokinechemokin
respons
also
observ
convalesc
asymptomat
case
restvinfect
cynomolgu
macaqu
high
viremia
shown
induc
secret
proinflammatori
cytokineschemokin
howev
far
limit
number
studi
impact
proinflammatori
cytokinechemokin
respons
convalesc
phase
restv
infect
studi
group
cynomolgu
macaqu
sampl
base
presenc
restv
npantigen
sera
analyz
antibodi
reaction
cytokin
chemokin
induct
evalu
presenc
neutral
antibodi
restv
found
antigp
respons
antinp
respons
close
correl
neutral
antibodi
respons
well
clearanc
viremia
sera
restvinfect
cynomolgu
macaqu
addit
high
concentr
proinflammatori
cytokin
chemokin
detect
convalesc
phase
specimen
data
suggest
antigp
respons
proinflammatori
cytokineschemokin
play
signific
role
recoveri
restv
infect
cynomolgu
macaqu
restv
npand
gp
specif
antibodi
neutral
antibodi
respons
viral
antigen
cynomolgu
macaqu
sera
restv
epizoot
twentyseven
serum
sampl
deriv
cynomolgu
macaqu
either
found
alreadi
dead
euthan
facil
avail
presenc
restv
np
antigen
evalu
antigencaptur
elisa
immunohistochemistri
antirestv
np
igg
evalu
use
igg
elisa
ifa
method
order
examin
whether
sera
contain
antigp
antibodi
employ
gp
specif
elisa
ifa
restv
gp
prepar
baculoviru
express
system
restv
gp
express
hela
cell
use
antigen
gp
specif
elisa
ifa
respect
antirestv
gp
igg
detect
serum
sampl
accord
elisa
wherea
remain
sampl
show
neg
reaction
nine
serum
sampl
posit
gp
antibodi
iggelisa
also
show
posit
reaction
ifa
one
serum
sampl
posit
ifa
serum
sampl
show
posit
reaction
either
gp
specif
iggelisa
ifa
consid
antigp
posit
tabl
interestingli
sera
deriv
cynomolgu
macaqu
acut
virem
phase
contain
detect
antigp
igg
although
often
contain
antinp
igg
next
attempt
detect
neutral
nt
antibodi
respons
sera
restvinfect
cynomolgu
macaqu
vsv
pseudotyp
restv
gp
vsvrestvgp
gfp
use
nt
assay
twelv
serum
sampl
neutral
vsvrestvgp
gfp
infect
nt
titer
rang
tabl
antigp
igg
detect
igg
elisa
sampl
neutral
activ
two
specimen
show
posit
respons
viral
antigen
agcaptur
elisa
thu
consid
collect
earli
seroconvers
phase
cynomolgu
macaqu
facil
euthanat
regardless
clinic
statu
possibl
cynomolgu
macaqu
combin
infect
simian
hemorrhag
fever
viru
shfv
anim
facil
therefor
immun
respons
restv
alway
reflect
clinic
manifest
reason
defin
convalesc
nonconvalesc
base
upon
serolog
find
noteworthi
among
serum
sampl
posit
viral
antigen
neg
nt
antibodi
ag
nt
nine
serum
sampl
neg
antigp
antibodi
wherea
two
sampl
neg
antinp
antibodi
hand
ten
serum
sampl
neg
viral
antigen
posit
nt
antibodi
ag
nt
posit
antigp
antinp
antibodi
find
indic
antigp
antibodi
may
therefor
increas
cynomolgu
macaqu
convalesc
phase
antigp
antibodi
rare
detect
acut
virem
phase
infect
ebola
viru
infect
trigger
express
sever
proinflammatori
cytokineschemokin
examin
whether
convalesc
restv
infect
correl
circul
proinflammatori
cytokineschemokin
eleven
restvinfect
cynomolgu
macaqu
serum
sampl
subject
multiplex
cytokin
analysi
sinc
know
infect
occur
cynomolgu
macaqu
still
unclear
whether
sera
repres
earli
late
stage
infect
use
seven
convalesc
phase
sera
ag
nt
four
acut
virem
phase
sera
ag
nt
among
serum
sampl
serum
sampl
avail
multiplex
assay
sinc
sera
heatinactiv
min
prior
subject
multiplex
analysi
cytokin
gmcsf
previous
shown
elev
restv
infect
cynomolgu
macaqu
could
measur
assay
found
concentr
sever
proinflammatori
cytokineschemokin
eg
significantli
higher
convalesc
acut
phase
sera
figur
observ
similar
previou
studi
show
elev
concentr
proinflammatori
cytokineschemokin
convalesc
asymptomat
human
case
contrast
concentr
five
cytokineschemokin
eg
differ
significantli
two
group
figur
furthermor
concentr
one
proinflammatori
chemokin
lower
convalesc
nonconvalesc
sera
figur
data
indic
might
therefor
involv
host
immun
respons
convalesc
phase
restv
infect
previous
develop
restv
npspecif
iggelisa
ifa
prove
use
seroepidemiolog
studi
cynomolgu
macaqu
restv
epizoot
philippin
assay
base
recombin
np
sensit
detect
restvspecif
antibodi
hand
antigp
antibodi
elicit
ebovinfect
human
case
believ
protect
role
lethal
ebov
infect
present
studi
order
gain
insight
igg
respons
recoveri
infect
restv
antinp
antigp
neutral
antibodi
level
viremia
serum
specimen
analyz
data
present
herein
show
antigp
respons
rather
antinp
respons
correl
lack
viremia
neutral
activ
sera
restvinfect
cynomolgu
macaqu
may
least
two
possibl
lack
antigp
igg
acut
phase
sampl
known
solubl
gp
sgp
contain
membran
anchor
secret
ebolavirus
infect
absorb
antigp
antibodi
possibl
apoptosi
lymphocyt
induc
restv
infect
result
host
immun
respons
may
thu
abrog
although
precis
mechan
action
still
unknown
like
igg
respons
restv
gp
induc
cynomolgu
macaqu
acut
phase
infect
sinc
cynomolgu
macaqu
facil
restv
epizoot
occur
euthan
sequenti
serum
specimen
cynomolgu
macaqu
avail
also
difficult
determin
cynomolgu
macaqu
becam
infect
restv
found
three
specimen
antigp
antibodi
obtain
dead
monkey
howev
difficult
conclud
whether
restv
infect
caus
death
possibl
succumb
infect
shfv
agent
predict
among
serum
sampl
examin
nine
acut
phase
sampl
posit
agelisa
immunohistochemistri
tabl
hand
one
serum
antigp
serum
sampl
ag
neg
therefor
cynomolgu
macaqu
consid
convalesc
phase
restv
infect
regard
presenc
antigp
antibodi
thought
use
indic
convalesc
cynomolgu
macaqu
infect
restv
aberr
proinflammatori
cytokineschemokin
signific
factor
implic
diseas
progress
ebovand
sudvinfect
human
case
experiment
infect
cynomolgu
macaqu
addit
balanc
proinflammatori
respons
believ
critic
factor
determin
diseas
outcom
focus
circul
inflammatori
cytokineschemokin
restvinfect
cynomolgu
macaqu
examin
relationship
convalesc
thu
found
concentr
sever
proinflammatori
cytokin
chemokin
significantli
higher
convalesc
sera
nonconvalesc
sera
gupta
et
al
recent
demonstr
convalesc
serum
sampl
obtain
bdbvinfect
human
case
includ
high
concentr
although
exact
profil
proinflammatori
cytokineschemokin
shown
studi
differ
report
gupta
et
al
differ
consid
like
due
differ
among
ebolavirus
restv
vs
bdbv
host
speci
cynomolgu
macaqu
vs
human
differ
relat
diseas
phase
sampl
obtain
possibl
upregul
proinflammatori
innat
immun
respons
contribut
recoveri
restv
infect
cynomolgu
macaqu
rhesu
monkey
experiment
infect
lethal
dose
ebov
antiinflammatori
cytokin
highli
elev
acut
phase
human
ebola
vhf
patient
increas
concentr
shown
fatal
case
thu
suggest
mix
antiinflammatori
respons
syndrom
mar
contribut
pathogenesi
hemorrhag
fever
caus
ebolavirus
sinc
cynomolgu
macaqu
involv
epizoot
euthan
affect
facil
actual
fate
cynomolgu
macaqu
clear
might
surviv
infect
data
obtain
use
sera
cynomolgu
macaqu
restv
epizoot
show
higher
respons
convalesc
phase
nonconvalesc
phase
figur
signific
differ
concentr
two
group
data
shown
suggest
unlik
ebolavirus
infect
restv
induc
mar
character
elev
induct
acut
phase
conclus
shown
antigp
respons
rather
antinp
respons
cynomolgu
macaqu
natur
infect
restv
specif
detect
convalesc
stage
restv
infect
addit
high
concentr
proinflammatori
cytokineschemokin
observ
convalesc
phase
therefor
antigp
respons
upregul
specif
proinflammatori
respons
might
use
indic
convalesc
restv
infect
cynomolgu
macaqu
studi
analyz
humor
respons
cynomolgu
macaqu
serum
sampl
collect
reston
outbreak
philippin
demonstr
antirestv
gp
respons
proinflammatori
innat
respons
play
signific
role
convalesc
restv
infect
cynomolgu
macaqu
twentyseven
cynomolgu
macaqu
serum
sampl
obtain
cynomolgu
macaqu
facil
philippin
restv
epizoot
occur
serum
specimen
affect
facil
collect
quarantin
philippin
nineteen
sampl
previous
subject
antigen
captur
elisa
nine
sampl
found
restv
antigenposit
remain
consid
antigenneg
serum
specimen
treat
minut
viru
cynomolgu
macaqu
serum
sampl
inactiv
neg
control
iggelisa
ifa
use
serum
sampl
cynomolgu
macaqu
collect
tsukuba
primat
research
center
tprc
japan
posit
control
iggelisa
ifa
two
rabbit
immun
four
time
histidinetag
ectodomain
restv
glycoprotein
gp
restv
gp
histidinetag
restv
gp
restv
prepar
purifi
describ
sera
collect
rabbit
inactiv
store
use
experi
anim
perform
accord
anim
experiment
guidelin
nation
institut
infecti
diseas
protocol
approv
institut
anim
care
use
committe
institut
permit
number
recombin
baculoviru
express
restv
gp
use
prepar
recombin
restv
gp
iggelisa
briefli
recombin
baculoviru
carri
ectodomain
restv
gp
ddbj
access
histidinetag
sequenc
infect
cell
multipl
infect
moi
cell
collect
wash
pb
lyse
pb
contain
nonidet
ice
min
centrifug
recombin
restv
gp
purifi
ni
agaros
bead
qiagen
hilden
germani
bind
kit
novagen
darmstadt
germani
purifi
recombin
restv
gp
use
iggelisa
specif
restv
gp
lysat
cell
infect
baculoviru
delet
polyhedrin
gene
similarli
process
use
neg
control
antigen
iggelisa
describ
ninetysix
well
plate
coat
restv
gp
neg
control
antigen
pb
incub
overnight
plate
wash
three
time
pb
contain
tween
pbst
pbst
contain
skim
milk
skimpbst
ad
well
incub
hr
cynomolgu
macaqu
sera
dilut
skimpbst
hyperimmun
rabbit
sera
fourfold
serial
dilut
skimpbst
one
hundr
microlit
serum
dilut
ad
antigenco
well
incub
hr
wash
three
time
pbst
well
react
either
hrpconjug
goat
antihuman
igg
h
l
zyme
hrpconjug
goat
antirabbit
igg
h
l
zyme
dilut
skimpbst
wash
three
time
pbst
abt
substrat
roch
diagnost
ad
well
plate
incub
minut
od
valu
well
nm
measur
adjust
od
valu
calcul
subtract
od
valu
well
coat
neg
control
antigen
well
coat
restv
gp
npspecif
iggelisa
similar
gp
specif
elisa
except
purifi
recombin
restv
np
histidin
tag
cterminu
previous
report
sum
od
valu
serum
dilut
specimen
calcul
design
elisa
index
iggelisa
mean
plu
three
standard
deviat
sd
elisa
indic
iggelisa
calcul
use
serum
sampl
uninfect
tprc
cynomolgu
macaqu
use
cutoff
valu
iggelisa
indirect
immunofluoresc
antibodi
assay
ifa
specif
restv
np
gp
ifa
specif
restv
np
report
previous
present
studi
restv
gp
specif
ifa
establish
use
stabli
restv
gp
express
hela
cell
hela
cell
line
purchas
american
type
cultur
collect
use
restv
gp
cdna
restv
subclon
mammalian
express
plasmid
gener
hela
cell
express
restv
gp
select
medium
contain
blasticidinshydrochlorid
sigma
st
loi
mo
transfect
use
fugen
hd
transfect
reagent
roch
diagnost
germani
cell
trypsin
wash
pb
mix
normal
hela
cell
spot
well
teflonco
glass
slide
air
dri
fix
aceton
room
temperatur
min
slide
store
use
slide
thaw
dri
use
serum
specimen
serial
dilut
pb
aliquot
dilut
appli
well
antigen
slide
incub
hr
humidifi
chamber
antigen
slide
wash
pb
react
per
well
fitcconjug
goat
antihuman
igg
h
l
zymax
lot
invitrogen
ca
usa
cynomolgu
macaqu
sera
fitcconjug
goat
antirabbit
igg
h
l
zymax
lot
invitrogen
ca
usa
rabbit
hyperimmun
sera
dilut
incub
hr
slide
wash
pb
cover
micro
cover
glass
slide
examin
stain
pattern
fluoresc
microscop
antibodi
titer
ifa
determin
reciproc
highest
dilut
show
posit
stain
restv
neutral
nt
assay
use
vsvrestvgp
gfp
vsv
pseudotyp
bear
restv
gp
vsvrestvgp
gfp
gener
essenti
accord
method
describ
vsv
pseudotyp
bear
sarscov
protein
except
use
present
studi
briefli
cell
prepar
well
plate
confluenc
cell
transfect
use
fugen
hd
cell
cultur
hr
inocul
vsv
gfp
pseudotyp
vsvg
protein
moi
adsorb
hr
wash
fc
cultur
hr
cultur
supernat
collect
centrifug
rpm
remov
cell
debri
thereaft
supernat
store
vsvrestvgp
gfp
infect
titer
vsvrestvgp
gfp
harbor
vsv
gfp
genom
determin
count
number
gfpposit
cell
fluoresc
microscop
upon
infect
vero
cell
describ
previous
briefli
vsvrestvgp
gfp
log
fold
serial
dilut
fc
inocul
vero
cell
seed
well
cultur
plate
cell
incub
co
incub
hr
gfpposit
cell
detect
count
fluoresc
microscop
keyenc
osaka
japan
infecti
unit
iu
pseudotyp
vsv
calcul
serum
sampl
serial
dilut
fc
aliquot
dilut
mix
volum
fc
contain
iu
vsvrestvgp
gfp
incub
hr
mixtur
inocul
vero
cell
incub
hr
number
gfpposit
infect
cell
count
serum
dilut
neutral
nt
identifi
multiplex
assay
cytokin
chemokin
cynomolgu
macaqu
sera
eleven
restvinfect
cynomolgu
macaqu
serum
sampl
inactiv
min
dilut
assay
diluent
suppli
human
cytokin
antibodi
bead
kit
invitrogen
ca
subject
multiplex
cytokin
analysi
use
luminex
instrument
luminex
co
austin
tx
accord
manufactur
instruct
human
cytokin
antibodi
bead
kit
previous
use
cynomolgu
macaqu
sera
crossreact
confirm
neg
control
use
sera
cynomolgu
macaqu
bred
tprc
investig
cytokin
concentr
serum
sampl
